• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19518 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     NIHR Health Technology Assessment programme Gastric Bypass, adjustable gastric Banding or Sleeve gastrectomy surgery to treat severe and complex obesity: a multi-centre randomised controlled trial (The By-Band-Sleeve Study)
2022     NIHR Health Technology Assessment programme POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes
2022     Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022     NIHR Health Technology Assessment programme The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022     NIHR Health Technology Assessment programme E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022     Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022     NIHR Health Technology Assessment programme Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2022     NIHR Health Technology Assessment programme RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022     NIHR Health Technology Assessment programme Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodules
2022     NIHR Health Technology Assessment programme Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial (HEAT)
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022     Medical Services Advisory Committee (MSAC) Genetic testing for childhood hearing impairment
2022     NIHR Health Technology Assessment programme The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022     Medical Services Advisory Committee (MSAC) Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer disease
2022     NIHR Health Technology Assessment programme Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022     NIHR Health Technology Assessment programme Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022     NIHR Health Technology Assessment programme Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease
2022     NIHR Health Technology Assessment programme VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot. The VIOLET Study
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     NIHR Health Technology Assessment programme Liaison Psychiatry: Measurement And Evaluation of Service Types, Referral patterns and Outcomes LP-MAESTRO
2022     NIHR Health Technology Assessment programme Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial
2022     NIHR Health Technology Assessment programme Comparison of ALitretinoin with PUVA as the first line treatment in patients with severe chronic HAnd eczema (ALPHA trial)
2022     NIHR Health Technology Assessment programme Early detection of neovascular age-related macular degeneration
2022     NIHR Health Technology Assessment programme Intravenous immunoglobulin in the management of encephalitis in children
2022     NIHR Health Technology Assessment programme Catheter Ablation versus thoracoscopic Surgical Ablation in long standing persistent Atrial Fibrillation (CASA-AF)
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2022     NIHR Health Technology Assessment programme The effectiveness of adjunctive medication management and contingency management to enhance adherence to medications for relapse prevention in alcohol dependence
2022     NIHR Health Technology Assessment programme Cerclage Suture Type for an Insufficient Cervix and its effect on Health outcomes (C-STICH)
2022     NIHR Health Technology Assessment programme At-Risk Registers Integrated into primary care to Stop Asthma crises in the UK (ARRISA-UK): a pragmatic cluster randomised trial with nested economic and process evaluations examining the effects of integrating at-risk asthma registers into primary care with internet-based training and support
2022     NIHR Health Technology Assessment programme StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): A randomised, double-masked, sham- controlled, clinical trial comparing low-voltage X-ray irradiation with as needed ranibizumab, to as needed ranibizumab monotherapy
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Mobility aids for people with physical disabilities
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of women with diastasis recti
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Return to work – persons with long-term sickleave or welfare recipients
2022     NIHR Health Technology Assessment programme Therapeutic Interventions for Stones of the Ureter (TISU): a multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic retrieval, for ureteric stones
2022     NIHR Health Technology Assessment programme TARGIT-B: An international randomised controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Swiss Federal Office of Public Health (FOPH) Medicines for dementia due to Alzheimer's disease and Parkinson's disease
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2022     NIHR Health Technology Assessment programme PUMA - Paediatric early warning system (PEWS): Utilisation and Mortality Avoidance. A prospective, mixed methods, before and after study identifying the evidence base for the core components of an effective PEWS and the development of an implementation package for implementation and use in the UK
2022     Swiss Federal Office of Public Health (FOPH) Thyroid function tests for the diagnosis of suspected primary or secondary thyroid dysfunction
2022     NIHR Health Technology Assessment programme Male synthetic sling versus Artificial urinary Sphincter Trial for men with urodynamic stress incontinence after prostate surgery: Evaluation by Randomised controlled trial (MASTER)
2022     NIHR Health Technology Assessment programme The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial
2022     Agency for Care Effectiveness (ACE) Disease-modifying therapies for treating multiple sclerosis
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for acute lymphoblastic leukaemia
2022     Agency for Care Effectiveness (ACE) Long-acting erythropoiesis-stimulating agents for treating anaemia in chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors, immune checkpoint inhibitors and everolimus for treating advanced renal cell cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced gastric cancer
2022     Agency for Care Effectiveness (ACE) Update of MOH list of subsidised drugs to include treatments for various cancer conditions
2022     NIHR Health Technology Assessment programme Mammographic surveillance in breast cancer patients aged 50 years or older
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating ALK mutation-positive advanced non-small-cell lung cancer
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for prostate cancer
2022     Agency for Care Effectiveness (ACE) Cetuximab and panitumumab for treating RAS wild-type colorectal cancer
2022     NIHR Health Technology Assessment programme PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Progestogen Therapy
2022     Agency for Care Effectiveness (ACE) Regorafenib and sunitinib for treating advanced gastrointestinal stromal tumours
2022     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease: a prospective longitudinal study in a multiethnic population
2022     Agency for Care Effectiveness (ACE) Dabrafenib in combination with trametinib for treating BRAF V600 mutation-positive anaplastic thyroid cancer
2022     Agency for Care Effectiveness (ACE) Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating differentiated thyroid cancer
2022     NIHR Health Technology Assessment programme Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
2022     Agency for Care Effectiveness (ACE) Immune checkpoint inhibitors and BRAK/MEK inhibitors for treating advanced malignant melanoma
2022     NIHR Health Technology Assessment programme Cluster randomised trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest (Airways-2)
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated multiple myeloma
2022     Agency for Care Effectiveness (ACE) Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours
2022     Agency for Care Effectiveness (ACE) Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2022     Agency for Care Effectiveness (ACE) Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022     Agency for Care Effectiveness (ACE) Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: optimal use of immunoglobulin in solid organ transplantation]
2022     Agency for Care Effectiveness (ACE) Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022     Agency for Care Effectiveness (ACE) Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022     Agency for Care Effectiveness (ACE) Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: biologic dose escalation - gastroenterology, rheumatology and dermatology]
2022     Agency for Care Effectiveness (ACE) PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Afstyla™ (rFVIII) – type A hemophilia]
2022     Agency for Care Effectiveness (ACE) Bevacizumab biosimilar for treating different types of cancers
2022     NIHR Health Technology Assessment programme The CRASH-3 Trial: Tranexamic acid for the treatment of significant traumatic brain injury
2022     Center for Evidence-based Practice (CEP) Restrictive red blood cell (RBC) transfusion thresholds: update
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022     NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2022     Swiss Federal Office of Public Health (FOPH) Denosumab (Prolia®) for the treatment of osteoporosis
2022     NIHR Public Health Research (PHR) programme E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2022     Swiss Federal Office of Public Health (FOPH) Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of medical care and services in long-term care facilities]
2022     Swiss Federal Office of Public Health (FOPH) Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: a look at Québec’s family medicine groups and a proposal to segment the population to support continuous quality improvement approaches based on health needs]
2022     Swiss Federal Office of Public Health (FOPH) Levothyroxine as a treatment for subclinical hypothyroidism
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services for the prevention and management of post COVID-19 conditions]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: helicopter emergency medical services (HEMS) - needs analysis and clientele identification]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: practices for screening or reducing psychological symptoms in individuals with a post-COVID-19 condition]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: molecular profiling of adult solid tumors - Focus Panel (Illumina) – 52 somatic biomarkers analysis]